Paul Cislo

1.7k total citations
40 papers, 869 citations indexed

About

Paul Cislo is a scholar working on Surgery, Oncology and Economics and Econometrics. According to data from OpenAlex, Paul Cislo has authored 40 papers receiving a total of 869 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Surgery, 11 papers in Oncology and 11 papers in Economics and Econometrics. Recurrent topics in Paul Cislo's work include Bladder and Urothelial Cancer Treatments (10 papers), Health Systems, Economic Evaluations, Quality of Life (10 papers) and Radiopharmaceutical Chemistry and Applications (8 papers). Paul Cislo is often cited by papers focused on Bladder and Urothelial Cancer Treatments (10 papers), Health Systems, Economic Evaluations, Quality of Life (10 papers) and Radiopharmaceutical Chemistry and Applications (8 papers). Paul Cislo collaborates with scholars based in United States, United Kingdom and Germany. Paul Cislo's co-authors include Durland Fish, Forrest Melton, Gwenaël Vourc’h, Alan G. Barbour, Maria A. Diuk‐Wasser, Roberto Cortinas, Jean I. Tsao, Jonas Bunikis, Joseph Piesman and Anne Gatewood Hoen and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Applied and Environmental Microbiology.

In The Last Decade

Paul Cislo

35 papers receiving 848 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul Cislo United States	9	503	452	203	192	182	40	869
Lin Zhan China	16	100 0.2×	487 1.1×	200 1.0×	48 0.3×	52 0.3×	30	795
Tom Dodd Australia	9	213 0.4×	173 0.4×	29 0.1×	65 0.3×	88 0.5×	19	428
Huanshun Wen China	13	125 0.2×	586 1.3×	60 0.3×	135 0.7×	235 1.3×	34	877
M. C. Prati Italy	15	212 0.4×	264 0.6×	86 0.4×	140 0.7×	13 0.1×	42	859
Gianni Gori Savellini Italy	17	66 0.1×	543 1.2×	41 0.2×	184 1.0×	99 0.5×	52	857
P. Gigase Belgium	22	184 0.4×	429 0.9×	30 0.1×	111 0.6×	19 0.1×	54	1.5k
Malcolm Lawson Australia	14	82 0.2×	86 0.2×	117 0.6×	42 0.2×	18 0.1×	26	620
Quentin Leroy France	10	166 0.3×	82 0.2×	116 0.6×	57 0.3×	25 0.1×	16	584
Eric Dahlstrom United States	14	199 0.4×	305 0.7×	9 0.0×	132 0.7×	93 0.5×	23	807
H. W. Casey United States	15	111 0.2×	89 0.2×	125 0.6×	45 0.2×	46 0.3×	36	623

Countries citing papers authored by Paul Cislo

Since Specialization

Citations

This map shows the geographic impact of Paul Cislo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Cislo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Cislo more than expected).

Fields of papers citing papers by Paul Cislo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Cislo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Cislo. The network helps show where Paul Cislo may publish in the future.

Co-authorship network of co-authors of Paul Cislo

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Cislo. A scholar is included among the top collaborators of Paul Cislo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Cislo. Paul Cislo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cislo, Paul, et al.. (2026). An oBservational retrospective Analysis of treatment patternS and Effectiveness of standard of CAre for Multiple Myeloma Patients Exposed to Lenalidomide and a Proteasome Inhibitor: BasecaMMp Study. Clinical Lymphoma Myeloma & Leukemia.

Fay, André P., Karim Fizazi, Nobuaki Matsubara, et al.. (2025). First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial. The Lancet Oncology. 26(4). 481–490. 1 indexed citations

Cislo, Paul, et al.. (2025). Symptom Alleviation/Resolution and Returns to Usual Health/Activities in Immunocompromised Adults with COVID-19 Treated with Nirmatrelvir-Ritonavir: Results from the EPIC-IC Trial. Infectious Diseases and Therapy. 14(12). 2763–2783.

Costa, Luciano J., Thomas W. LeBlanc, Hans Tesch, et al.. (2024). An Indirect Comparison of Elranatamab's Progression-Free Survival, Duration of Response, and Overall Survival from MagnetisMM-3 Versus Real-World External Control Arms in Triple-Class Refractory Multiple Myeloma. Blood. 144(Supplement 1). 2401–2401.

Fay, André P., Karim Fizazi, Nobuaki Matsubara, et al.. (2023). 1811P Patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA: Results from a phase III (TALAPRO-2) study. Annals of Oncology. 34. S980–S981. 1 indexed citations

Cappelleri, Joseph C. & Paul Cislo. (2023). Analysis of Clinically Meaningful Change on Patient-Reported Outcomes: Renewed Insights About Covariate Adjustment. Journal of Biopharmaceutical Statistics. 35(5). 812–825. 2 indexed citations

Ren, Jinma, Paul Cislo, Joseph C. Cappelleri, Patrick Hlavacek, & Marco DiBonaventura. (2023). Comparing g-computation, propensity score-based weighting, and targeted maximum likelihood estimation for analyzing externally controlled trials with both measured and unmeasured confounders: a simulation study. BMC Medical Research Methodology. 23(1). 18–18. 12 indexed citations

Powles, Thomas, Paul Cislo, Jane Chang, et al.. (2023). Estimated net benefit of avelumab (AVE) + best supportive care (BSC) vs BSC alone for patients (pts) with advanced urothelial carcinoma (aUC) using a quality-adjusted time without cancer symptoms or toxicity (Q-TWiST) analysis.. Journal of Clinical Oncology. 41(16_suppl). 4515–4515. 2 indexed citations

Grivas, Petros, Evgeny Kopyltsov, Po‐Jung Su, et al.. (2022). Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma. European Urology. 83(4). 320–328. 32 indexed citations

10.

Conaghan, Philip G., Lucy Abraham, Lars Viktrup, & Paul Cislo. (2022). Impact of tanezumab on health status, non-work activities and work productivity in adults with moderate-to-severe osteoarthritis. BMC Musculoskeletal Disorders. 23(1). 106–106. 3 indexed citations

11.

Kapetanakis, Venediktos, et al.. (2021). PCN217 Health State Utility Values of Patients With Locally Advanced or Metastatic Urothelial Carcinoma: Analysis Based on the JAVELIN Bladder 100 Trial. Value in Health. 24. S60–S60.

12.

Peipert, John Devin, Jane Chang, Alessandra di Pietro, et al.. (2021). PCN214 Responsiveness and Responder Definitions for the NCCN/FACT Bladder Symptom Index (NFBISI-18) in Individuals With Locally Advanced or Metastatic Urothelial Cancer (UC). Value in Health. 24. S59–S60. 2 indexed citations

13.

Cislo, Paul, Birol Emir, Javier Cabrera, Benjamin Li, & Demissie Alemayehu. (2021). Finite Mixture Models, a Flexible Alternative to Standard Modeling Techniques for Extrapolated Mean Survival Times Needed for Cost-Effectiveness Analyses. Value in Health. 24(11). 1643–1650. 4 indexed citations

14.

Doshi, Gurjyot K., Murtuza Bharmal, Hemant Phatak, et al.. (2018). Patient Characteristics And Treatment Patterns From Spear-Bladder: Study Informing Treatment Pathway Decision In Bladder Cancer. Value in Health. 21. S49–S49. 1 indexed citations

15.

Parker, Christopher, Lin Zhan, Paul Cislo, et al.. (2016). Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial. European Journal of Cancer. 71. 1–6. 36 indexed citations

16.

Nilsson, Sten, Paul Cislo, Oliver Sartor, et al.. (2016). Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Annals of Oncology. 27(5). 868–874. 132 indexed citations

17.

Cislo, Paul, et al.. (2015). Cost-Effectiveness of Radium-223 Dichloride (Radium-223) In Alsympca: A Cost-Effectiveness Analysis of Radium-223+Best Standard of Care (Bsoc) Compared With Placebo+Bsoc In Treatment of Castration-Resistant Prostate Cancer (Crpc) And Symptomatic Bone Metastases In Canada. Value in Health. 18(3). A202–A202. 2 indexed citations

18.

Zhan, Liying, et al.. (2015). 1230 Effect of radium-233 dichloride (Ra-223) on hospitalization and its economic implications in ALSYMPCA trial. European Journal of Cancer. 51. S183–S183. 1 indexed citations

19.

Stillman, Ipek Özer, et al.. (2013). A Cost-Effectiveness Analysis of Axitinib and Sorafenib for 2nd Line Treatment of Advanced Renal Cell Carcinoma After Failure of Cytokines in the United States. Value in Health. 16(7). A410–A410. 2 indexed citations

20.

Diuk‐Wasser, Maria A., Anne Gatewood Hoen, Paul Cislo, et al.. (2012). Human Risk of Infection with Borrelia burgdorferi, the Lyme Disease Agent, in Eastern United States. American Journal of Tropical Medicine and Hygiene. 86(2). 320–327. 225 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact